DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181296

Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes

Amitesh Kumar Chatterjee

Abstract


Background: In patient with type 2 diabetes (T2D) inadequately controlled on monotherapy, teneligliptin is efficacious and safe as add-on to treatment with oral antidiabetic drugs (OADs) or insulin. Data on efficacy of teneligliptin in Indian patients is relatively sparse. Aim of the study was to assess the efficacy of teneligliptin used as add-on treatment in patients inadequately controlled on monotherapy with OADs or insulin.

Methods: We retrospectively evaluated the electronic database at our endocrinology clinic from East India. Patients who were treated with teneligliptin (20 mg/day) as add-on to monotherapy with OADs or insulin were identified, and data analysed. Primary assessment parameters were change in glycosylated haemoglobin (HbA1c %), fasting plasma glucose (FPG, mg/dL) and post-prandial plasma glucose (PPG, mg/dL) over 12-week from the addition of teneligliptin. Paired t test and McNemar test applied to derive statistical significance of paired continuous and categorical variables respectively.

Results: In 88 patients, teneligliptin was used as add-on treatment in 77.3% and 22.7% patients receiving OAD and insulin as monotherapy respectively. Mean age of population was 48.3±15.1 years and 67% were males. From baseline to 12-weeks, there was significant change in HbA1c (9.6±2.1 to 8.4±1.2%, P<0.001), FPG (181.4±54.5 to 140.9±27.1 mg/dL, P<0.001) and PPG (273.7±75.6 to 201.1±47.7 mg/dL, P<0.001). Reduction in these glycemic parameters was significant in patients with teneligliptin as add-on to either OADs or insulin. Overall, 12.5% patients reached the target HbA1c of <7% after 12-week treatment (P=0.004).

Conclusions: In patients who are uncontrolled on monotherapy with either OADs or insulin, addition of teneligliptin resulted in significant reduction of HbA1c, FPG and PPG after 12-week treatment. This establishes usefulness of teneligliptin in Indian patients with T2D. A larger, randomized, comparative study with other gliptins is warranted.


Keywords


Blood glucose, Diabetes, HbA1c, Indian, Monotherapy, Teneligliptin

Full Text:

PDF

References


International Diabetes Federation. Diabetes Atlas. 7th Edition 2015:144. Available at http://www. diabetesatlas.org/resources/2015-atlas.html. Accessed on 22 October 2017.

Tripathy JP, Thakur JS, Jeet G, Chawla S, Jain S, Pal A, Prasad R. Burden and risk factors of dyslipidemia-results from a STEPS survey in Punjab India. Diabetes Metabolic Syndrome: Clinical Research & Reviews. 2017;11:S21-7.

American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2017;40:S64-S74.

Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami O. Teneligliptin in management of type 2 diabetes mellitus. Diabetes, Metab Syndr Obes Targets Ther. 2016;9:251-60.

Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab. 2012;14:1040-6.

Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:810-8.

Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes. J Clin Med Res. 2014;6:287-94.

Kim MK, Rhee E-J, Han KA, Woo AC, Lee M-K, Ku BJ, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes. Metab. 2015;17:309-12.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2010;21(2):262-8.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4:576-84.

Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, et al. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther. 2014;16:1-6.

Ghosh S, Trivedi S, Snyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (treat‑India study). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2016;9:347-53.

Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM. Should studies of diabetes treatment stratification correct for baseline HbA1c? PLoS One. 2016;11(4):1-14.

Morishita R, Nakagami H. Teneligliptin: expectations for its pleiotropic action. Expert Opin Pharmacother. 2015;16:417-26.

Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y, Tsukamoto T. Safety and efficacy of teneligliptin: A novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. Int Urol Nephrol. 2014;46:427-32.

Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, et al. Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol. 2016;15:76.